European Healthcare Expenditure on Pharmaceuticals and Medical Non-Durable Goods by All Financing Schemes by Country

In 2024, Malta leads European countries with 4.04% of GDP spent on pharmaceuticals and medical non-durable goods, following steady growth. Noteworthy increases from 2023 include Bulgaria (0.15%) and Greece (1.23%), while Slovakia and Hungary saw slight decreases. Compared to previous years, Portugal, Iceland, and Malta showcase significant positive variations, indicating enhancing focus or financial initiatives. In contrast, Ireland, Belgium, and United Kingdom report declines, possibly reflecting policy shifts or economic challenges.

Future trends to observe include the impact of digital health technology integration and personalized medicine initiatives. Economic and policy environments across Europe may either amplify or dampen expenditures, particularly in high-growth or declining countries. Monitoring government policies and technological advancements will be essential in predicting future trends. Potential shifts toward more sustainable healthcare financing may also influence spending patterns.